InVitro International Engages Askew Kabala and Company, Inc. to Further Advance Its Corporate Growth Plan
InVitro International (OTCQB: IVRO) has announced the engagement of Askew Kabala and Company, Inc. (AKC) as a consultant to support and advance the company's corporate growth plan. AKC will provide business advising, investment banking, management, and strategy services to IVRO. The consulting firm will offer executive and organizational support, including strategy refinement, planning, and operational review.
IVRO CEO W. Richard Ulmer expressed enthusiasm about the partnership, stating that the company is adapting well to post-Covid-19 and inflationary times by adding guidance from experienced professionals. The engagement with AKC comes in the final month of IVRO's Fiscal 2024 Year, signaling a strategic move to enhance the company's growth trajectory.
InVitro International (OTCQB: IVRO) ha annunciato l'ingaggio di Askew Kabala and Company, Inc. (AKC) come consulente per supportare e promuovere il piano di crescita aziendale. AKC fornirà consulenze aziendali, servizi di investment banking, gestione e strategia a IVRO. La società di consulenza offrirà supporto esecutivo e organizzativo, incluso raffinamento della strategia, pianificazione e revisione operativa.
Il CEO di IVRO, W. Richard Ulmer, ha espresso entusiasmo per la partnership, affermando che l'azienda si sta adattando bene all'era post-Covid-19 e all'inflazione, aggiungendo il supporto di professionisti esperti. L'ingaggio con AKC avviene nell'ultimo mese dell'anno fiscale 2024 di IVRO, segnando una mossa strategica per migliorare la traiettoria di crescita dell'azienda.
InVitro International (OTCQB: IVRO) ha anunciado la contratación de Askew Kabala and Company, Inc. (AKC) como consultor para apoyar y avanzar el plan de crecimiento corporativo de la empresa. AKC proporcionará asesoramiento empresarial, banca de inversión, gestión y servicios de estrategia a IVRO. La firma de consultoría ofrecerá apoyo ejecutivo y organizativo, incluyendo afinación de estrategia, planificación y revisión operacional.
El CEO de IVRO, W. Richard Ulmer, expresó entusiasmo por la asociación, afirmando que la empresa se está adaptando bien a los tiempos post-Covid-19 e inflacionarios al agregar la orientación de profesionales experimentados. La colaboración con AKC se produce en el último mes del año fiscal 2024 de IVRO, lo que señala un movimiento estratégico para mejorar la trayectoria de crecimiento de la empresa.
InVitro International (OTCQB: IVRO)는 Askew Kabala and Company, Inc. (AKC)를 컨설턴트로 채용하여 회사의 성장 계획을 지원하고 발전시키기로 발표했습니다. AKC는 IVRO에 비즈니스 자문, 투자 은행업, 관리 및 전략 서비스를 제공합니다. 이 컨설팅 회사는 전략 수정, 계획 및 운영 검토를 포함하여 경영 및 조직 지원을 제공합니다.
IVRO의 CEO인 W. Richard Ulmer는 파트너십에 대한 열정을 표명하며, 회사가 경험이 풍부한 전문가의 지침을 추가하여 포스트-코비드-19 및 인플레이션 시대에 잘 적응하고 있다고 언급했습니다. AKC와의 계약은 IVRO의 2024 회계연도의 마지막 달에 체결되었으며, 이는 회사의 성장 궤적을 강화하기 위한 전략적 조치를 나타냅니다.
InVitro International (OTCQB: IVRO) a annoncé l'engagement d'Askew Kabala and Company, Inc. (AKC) en tant que consultant pour soutenir et faire avancer le plan de croissance de l'entreprise. AKC fournira à IVRO des conseils commerciaux, des services de banque d'investissement, de gestion et de stratégie. La société de conseil proposera un soutien exécutif et organisationnel, y compris le perfectionnement de la stratégie, la planification et la révision opérationnelle.
Le PDG d'IVRO, W. Richard Ulmer, a exprimé son enthousiasme pour ce partenariat, déclarant que l'entreprise s'adapte bien à l'ère post-Covid-19 et à l'inflation en ajoutant des conseils d'experts. L'engagement avec AKC intervient dans le dernier mois de l'année fiscale 2024 d'IVRO, signalant un mouvement stratégique pour améliorer la trajectoire de croissance de l'entreprise.
InVitro International (OTCQB: IVRO) hat die Beauftragung von Askew Kabala and Company, Inc. (AKC) als Berater bekannt gegeben, um den Unternehmenswachstumsplan zu unterstützen und voranzutreiben. AKC wird geschäftliche Beratung, Investment Banking, Management und Strategiedienste für IVRO bereitstellen. Die Beratungsgesellschaft bietet Unterstützung auf der Führungsebene und organisatorische Unterstützung, einschließlich Strategieoptimierung, Planung und operativer Überprüfung.
Der CEO von IVRO, W. Richard Ulmer, äußerte sich begeistert über die Partnerschaft und erklärte, dass das Unternehmen sich gut an die Zeit nach Covid-19 und an Inflationszeiten anpasst, indem es die Anleitung erfahrener Fachleute hinzufügt. Die Zusammenarbeit mit AKC erfolgt im letzten Monat des Geschäftsjahres 2024 von IVRO und signalisiert einen strategischen Schritt zur Verbesserung der Wachstumskurve des Unternehmens.
- Engagement of experienced consulting firm Askew Kabala and Company, Inc. to support corporate growth plan
- Addition of business advising, investment banking, management, and strategy services
- Potential for improved strategy refinement, planning, and operational review
- None.
Placentia, California--(Newsfile Corp. - September 3, 2024) - Today InVitro International (OTCQB: IVRO) is pleased to announce that it has engaged Askew Kabala and Company, Inc. as consultant to the company. AKC will act in a business advising, investment banking, management and strategy role to support and advance IVRO's previously announced corporate growth plan. AKC will provide executive and organizational support, including strategy refinement, planning and operational review & more where needed & appropriate.
IVRO CEO, W. Richard Ulmer, said: "InVitro believes it is adapting well to post-Covid '19 & inflationary times by adding guidance from experienced minds with an outstanding past performance record. We are delighted to have met and now partnered with Ron Askew and his team in this final month of our Fiscal '24 Year."
About InVitro International, Inc.
InVitro International, Inc., headquartered in Placentia, California, was founded in 1985 and is a customer and technology-driven provider of non-animal testing methods. The Company's testing technologies are designed to produce data regarding corrosivity and ocular/dermal irritation, which correlate with animal and human test results. IVRO's technology is commercialized globally through test kits and partner laboratory services.
This release may contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance, or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by forward looking statements. These risks and uncertainties include but are not limited to acceptance of the Company's technology by customers or regulatory agencies, changes in market conditions and other competitive factors. The forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update such statements.
Company Contact:
W. Richard Ulmer
Chief Executive Officer and Chairman
(800)246-8487
invitro@invitrointl.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/221834
FAQ
What consulting firm has InVitro International (IVRO) engaged to support its growth plan?
What services will Askew Kabala and Company provide to InVitro International (IVRO)?
When did InVitro International (IVRO) announce its engagement with Askew Kabala and Company?
How does InVitro International (IVRO) view its adaptation to post-Covid-19 and inflationary times?
